++
Rare and severe type of cholestasis liver disease, beginning in infancy and progressing to cirrhosis before adolescence.
++
PFIC Syndrome; Byler Disease; Fatal Intrahepatic Cholestasis; MDR 3 Deficiency; Progressive Intrahepatic Cholestasis with Elevated Serum Gamma-Glutamyltransferase Syndrome.
++
First described by Clayton, in 1965, in an Amish descendant of Jacob Byler.
++
Estimated 1:50,000 to 1: 100,000. Fewer than 200 patients have been reported for the low-GGT PFIC, whereas less than 20 are known in the high-GGT PFIC type. It is a lethal medical condition in childhood if not treated. Males and females are affected equally. PFIC represents 10 to 15% of chronic cholestasis and accounts for approximately 10% of pediatric liver transplants.
++
There are five types recognized:
++
Cholestasis Progressive Familial Intrahepatic Type I (PFIC Syndrome Type I; Byler Disease; Fatal Intrahepatic Cholestasis): Low level of gamma-glutamyl transferase (GGT); gene ATP8B1 (previously termed FIC 1) mapped on 18q21.
Cholestasis Progressive Familial Intrahepatic Type II (PFIC Syndrome Type II): Low level of γGT; gene ABCB11 (previously termed BSEP) mapped on 2q24.
Cholestasis Progressive Familial Intrahepatic Type III (PFIC Syndrome Type III; MDR 3 Deficiency; Progressive Intrahepatic Cholestasis with Elevated Serum Gamma-Glutamyltransferase Syndrome): High level of γGT; gene ABCB4 mapped on 7q21.1.
Cholestasis Progressive Familial Intrahepatic Type IV: Normal or mildly increased γGT, gene TJP2 mapped on 9q21.11.
Cholestasis Progressive Familial Intrahepatic Type V (Cholestasis Progressive Familial Intrahepatic Neonatal form): Low or normal serum levels of γGT and increased α-fetoprotein; gene NR1H4 mapped on 12q23.1.
++
Autosomal recessive (majority of patients), also autosomal dominant with variable penetrance, or sporadic. Type II is found in the Middle East, Greenland, and Sweden.
++
Mutations of the ATP8B1 encoding for the P-type ATPase 3 result in a reduction of phosphatidylserine and phosphatidylethanolamine on the inner leaflet of the plasma membrane leading to a reduction in the canalicular lumen due to a high concentration of bile salts and an increased concentration of bile acids in hepatocytes. Mutations of the ABCB11 gene, which encodes for the ATP-dependent transporter result in reduced bile salt secretion and bile flow leading to cholestasis. Mutations in the ABCB4 gene encoding for the MDR3 protein result in a high biliary bile salt to phosphatidylcholine ratio. The phosphatidylcholine prevents injury to the bile epithelium from hydrophobic bile salts. An altered bile salt/phospholipid ratio destabilizes micelles leading to cholesterol crystallization and lithogenicity of bile. Mutations in TJP2 gene encoding for the tight junction protein 2 or zona-occludens 2. This is a cytoplasmic component of cell-cell junctional complexes expressed in most epithelia where they create a link between the transmembrane tight junction proteins and the actin cytoskeleton ...